Backed by partner Sanofi, Earendil will expand the utility of its AI-driven drug discovery platform, while progressing its more than 40-strong drug pipeline.
Wegovy HD’s approval came on the cusp of the drug’s patent expiry in India and China, which leaves it vulnerable to biosimilar competition in these regions.
